MoonLake Debt To Equity from 2010 to 2025

MLTX Stock  USD 40.58  0.46  1.15%   
MoonLake Immunotherapeuti Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2025. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.00000633
Current Value
0.000007
Quarterly Volatility
0.3223529
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check MoonLake Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MoonLake Immunotherapeuti's main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.3 K, Other Operating Expenses of 34.1 M or Total Operating Expenses of 150.2 B, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0072. MoonLake financial statements analysis is a perfect complement when working with MoonLake Immunotherapeuti Valuation or Volatility modules.
  
Check out the analysis of MoonLake Immunotherapeuti Correlation against competitors.

Latest MoonLake Immunotherapeuti's Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of MoonLake Immunotherapeutics over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. MoonLake Immunotherapeuti's Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MoonLake Immunotherapeuti's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.01 %10 Years Trend
Pretty Stable
   Debt To Equity   
       Timeline  

MoonLake Debt To Equity Regression Statistics

Arithmetic Mean(0.08)
Coefficient Of Variation(406.45)
Mean Deviation0.15
Median0.0005
Standard Deviation0.32
Sample Variance0.10
Range1.2958
R-Value(0.19)
Mean Square Error0.11
R-Squared0.04
Significance0.47
Slope(0.01)
Total Sum of Squares1.56

MoonLake Debt To Equity History

2025 7.0E-6
2024 6.0E-6
2023 0.007679
2022 0.005779
2021 -1.29

About MoonLake Immunotherapeuti Financial Statements

MoonLake Immunotherapeuti investors use historical fundamental indicators, such as MoonLake Immunotherapeuti's Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in MoonLake Immunotherapeuti. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for MoonLake Stock Analysis

When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.